A pilot study of eicosapentaenoic acid therapy for ribavirin-related anemia in patients with chronic hepatitis C.
One of the major side effects of ribavirin/interferon alpha combination therapy for chronic hepatitis C is hemolytic anemia. One of the causes of hemolytic anemia is considered to be decreasing deformability of erythrocytes resulting from the accumulation of phosphorylated ribavirin in erythrocytes. The administration of eicosapentaenoic acid (EPA), which has a wide variety of pharmacological actions, increases the deformability of erythrocytes. We conducted an uncontrolled pilot study of EPA therapy for patients with ribavirin-related anemia. Six patients with chronic hepatitis C, who had developed anemia while receiving combination therapy, were treated with an oral ethyl ester of EPA (1800 mg/day) for two months. The hemoglobin level of all six patients increased following EPA therapy. The mean hemoglobin level significantly increased from 10.8 g/dl to 11.4 g/dl one month after therapy was initiated (P<0.05), and this level was obtained again one month later (11.5 g/dl). None of the patients developed an adverse reaction. These findings suggest that EPA has a beneficial effect in patients with ribavirin-related anemia. Further study is required to confirm our results.
Ide
Tatsuya
T
Second Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. ide@med.kurume-u.ac.jp
Okamura
Takashi
T
Kumashiro
Ryukichi
R
Koga
Yuriko
Y
Hino
Teruko
T
Hisamochi
Akiko
A
Ogata
Kei
K
Tanaka
Kazuo
K
Kuwahara
Reiichiro
R
Seki
Ritsuko
R
Sata
Michio
M
D000328:Adult; D000740:Anemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy*; D000998:Antiviral Agents / Q000009:adverse effects*; D015118:Eicosapentaenoic Acid / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins; D017701:Reticulocyte Count; D012254:Ribavirin / Q000009:adverse effects*
D000998:Antiviral Agents; D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D015118:Eicosapentaenoic Acid